Enhancing anti-melanoma outcomes in mice using novel chitooligosaccharide nanoparticles loaded with therapeutic survivin-targeted siRNA
X Liu, L Chen, Y Zhang, X Xin, L Qi, M Jin… - European Journal of …, 2021 - Elsevier
Melanoma anti-tumor therapy remains a challenge. SiRNA-based therapies provide a
powerful means, but limitations remain in its pharmaceutical applications owing to the lack of …
powerful means, but limitations remain in its pharmaceutical applications owing to the lack of …
Enhancing anti-melanoma outcomes in mice using novel chitooligosaccharide nanoparticles loaded with therapeutic survivin-targeted siRNA
X Liu, L Chen, Y Zhang, X Xin, L Qi… - … : official journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Melanoma anti-tumor therapy remains a challenge. SiRNA-based therapies provide a
powerful means, but limitations remain in its pharmaceutical applications owing to the lack of …
powerful means, but limitations remain in its pharmaceutical applications owing to the lack of …
Enhancing anti-melanoma outcomes in mice using novel chitooligosaccharide nanoparticles loaded with therapeutic survivin-targeted siRNA.
X Liu, L Chen, Y Zhang, X Xin, L Qi, M Jin… - European Journal of …, 2020 - europepmc.org
Melanoma anti-tumor therapy remains a challenge. SiRNA-based therapies provide a
powerful means, but limitations remain in its pharmaceutical applications owing to the lack of …
powerful means, but limitations remain in its pharmaceutical applications owing to the lack of …